Review

Functions and Regulatory Mechanisms of lncRNAs in Skeletal Myogenesis, Muscle Disease and Meat Production

Shanshan Wang 1,2,†, Jianjun Jin 1,2,†, Zaiyan Xu 1,3 and Bo Zuo 1,2,4,*

1 Key Laboratory of Swine Genetics and Breeding of the Ministry of Agriculture and Rural Affairs, Huazhong Agricultural University, Wuhan 430070, China
2 Key Laboratory of Agriculture Animal Genetics, Breeding and Reproduction of the Ministry of Education, Huazhong Agricultural University, Wuhan 430070, China
3 Department of Basic Veterinary Medicine, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China
4 The Cooperative Innovation Center for Sustainable Pig Production, Wuhan 430070, China
* Correspondence: zuobo@mail.hzau.edu.cn
† These authors contributed equally to the work.

Received: 17 July 2019; Accepted: 17 September 2019; Published: 19 September 2019

Abstract: Myogenesis is a complex biological process, and understanding the regulatory network of skeletal myogenesis will contribute to the treatment of human muscle related diseases and improvement of agricultural animal meat production. Long noncoding RNAs (lncRNAs) serve as regulators in gene expression networks, and participate in various biological processes. Recent studies have identified functional lncRNAs involved in skeletal muscle development and disease. These lncRNAs regulate the proliferation, differentiation, and fusion of myoblasts through multiple mechanisms, such as chromatin modification, transcription regulation, and microRNA sponge activity. In this review, we presented the latest advances regarding the functions and regulatory activities of lncRNAs involved in muscle development, muscle disease, and meat production. Moreover, challenges and future perspectives related to the identification of functional lncRNAs were also discussed.

Keywords: lncRNA; myogenesis; muscle disease; meat production

1. Introduction

Skeletal muscle is a heterogeneous organ composed of muscle fibers, the basement membrane, muscle satellite cells, and nerves [1]. In animal production, skeletal muscles are the main resources of animal protein for human consumption, and the growth and development of skeletal muscle directly influence animal meat quantity and quality. In medicine, abnormal regulation of skeletal muscle leads to many types of muscle disease, such as muscular atrophy, muscular dystrophy, muscular hypertrophy, and myosarcoma. Therefore, understanding the regulatory network of myogenesis could contribute to improved agricultural animal meat production, and to treating muscle diseases. During embryonic development, skeletal muscle originates from the myotome, and further forms myogenic progenitor cells under the regulation of the Shh, Notch and Wnt signaling pathways [2]. Muscle progenitor cells express paired box 3 (Pax3) and paired box 7 (Pax7) genes, and migrate to the limbs and trunk. Pax3 and Pax7 are upstream regulators that can induce expression of the myogenic factor 5 (Myf5) and myogenic differentiation 1 (MyoD), thus promoting the differentiation of muscle progenitor cells to myoblasts [3–5]. Overexpression of Pax3 and Pax7 can lead to excessive proliferation of myoblasts [6]. Skeletal myogenesis is an orderly process regulated by a series of muscle-specific
transcription factors, including MyoD, myogenin (MyoG), Myf5, myogenic regulatory factor 4 (MRF4), and myocyte enhancer factor 2 (MEF2) \[7,8\]. Myogenesis requires these transcription factors to be expressed at the right time and location \[9,10\]. For example, MyoD overexpression converts fibroblasts into myoblasts and leads to the subsequent fusion into myotubes \[11,12\]. MyoG knockdown reverses terminal muscle cell differentiation \[13,14\]. In addition, myogenesis is also regulated by epigenetic modification. For example, myogenesis is accompanied by dynamic changes in global chromosome modification, especially histone modification in myogenic genes \[15–19\]. During postnatal muscle development, muscle satellite cells are divided into two groups; one of which continues to proliferate and differentiate to form new muscle fibers. The other group is stored in the basement membrane as muscle stem cells, which are quiescent under normal conditions \[20,21\]. Once the muscle is injured or stimulated, resting muscle satellite cells are activated immediately to express the Pax7 gene. These satellite cells then begin to proliferate, migrate, and differentiate, fusing to form new muscle fibers to supplement the injured site \[22,23\]. Moreover, muscle regeneration is regulated by myogenic regulatory factors, the immune system, epigenetic modification, and the satellite cell microenvironment \[17,19,22,24,25\].

Although 80% of the eukaryotic genome is transcribed, only 2% of transcripts are translated into proteins \[26\]. Noncoding transcripts account for the vast majority of eukaryotic transcripts. The noncoding RNAs mainly include microRNAs (miRNAs), Piwi-interacting RNAs (piRNAs), circular RNAs (circRNAs), and long noncoding RNAs (lncRNAs). In this article, we focus primarily on lncRNAs, which are more than 200 nucleotides in length and have no protein-coding capacity \[27\]. Most lncRNAs are transcribed by RNA polymerase II, 5′ end capped, 3′ end poly(A) tailed, and post-transcription spliced \[28–30\]. Although lncRNAs are less abundant, less evolutionarily conserved, and have fewer exons compared to mRNA, their expression patterns are more spatio-temporally specific \[31–33\]. In the last decade, an increasing number of studies have indicated that lncRNAs participate in diverse cell and tissue development processes, such as X chromosome inactivation, genomic imprinting, stem cell maintenance, embryonic development, myogenesis, immunity, and tumorigenesis \[34–39\]. lncRNAs exert their functions through diverse mechanisms, including by regulating chromosome structures, gene transcription, mRNA stability and translation, and post-translational modification \[32\]. Here, we review recent advances regarding the importance of lncRNAs in skeletal muscle development, regeneration, and disease.

### 2. Functions and Mechanisms of lncRNAs in Muscle Development and Regeneration

Thousands of lncRNAs have been detected in skeletal muscles. However, the function of most lncRNAs in muscle is still unclear, and only a small fraction of lncRNAs have been characterized. These lncRNAs exert functional roles through multiple mechanisms, including chromosome modification, transcription activation, molecular sponge activity, competitive binding, mRNA translation, and protein stability (Figure 1 and Table 1).

| LncRNAs | Location | Function | Mechanism | Muscle Disease | Ref. |
|---------|----------|----------|-----------|---------------|-----|
| SYISL   | Nucleus/Cytoplasm | Promotes proliferation, inhibits differentiation and muscle regeneration | Interacts with PRC2 | Unknown | [40] |
| Neat1   | Nucleus | Promotes proliferation and regeneration, inhibits differentiation | Interacts with EZH2 | Unknown | [14] |
| Malat1  | Nucleus | Inhibits differentiation and regeneration | Interacts with Suv39h1 | Unknown | [41] |
| Linc-YY1| Nucleus | Promotes differentiation and regeneration | Interacts with YY1/PRC2 | Unknown | [42] |
| Linc-RAM| Nucleus/Cytoplasm | Promotes muscle growth and regeneration | Interacts with MyoD | Unknown | [43] |
| LncRNAs       | Location          | Function                                      | Mechanism                                                        | Muscle Disease | Ref.       |
|--------------|-------------------|-----------------------------------------------|------------------------------------------------------------------|----------------|------------|
| Dum          | Nucleus/Cytoplasm | Promotes differentiation and regeneration     | Interacts with Dnmts                                             | Unknown        | [44]       |
| Myolinc      | Nucleus           | Promotes differentiation and regeneration     | Interacts with TDP-43                                            | Unknown        | [45]       |
| Myoparr      | Nucleus           | Inhibits proliferation, promotes differentiation | Interacts with Ddx17/PCAF                                        | Muscle atrophy | [46]       |
| Irm          | Nucleus           | Promotes differentiation and regeneration     | Interacts with MEF2D                                             | Unknown        | [47]       |
| MUNCT        | Nucleus           | Promotes differentiation                      | Induces MyoD, MyoG, Myh3 expression                              | Unknown        | [48,49]   |
| Meg3         | Nucleus           | Promotes skeletal development during regeneration | Interacts with PRC2                                             | Unknown        | [50,51]   |
| SRA          | Nucleus           | Promotes differentiation                      | Assembly of p68/p72/MyoD coregulators                            | Unknown        | [52]       |
| Lnc-MD1      | Cytoplasm         | Promotes differentiation                      | MiR-133, miRNA-135 molecular sponge                             | Muscle atrophy | [53]       |
| MAR1         | Cytoplasm         | Promotes differentiation and muscle growth    | MiR-487b molecular sponge                                       | Muscle atrophy | [54,55]   |
| Lnc-mg       | Nucleus/Cytoplasm | Promotes differentiation and regeneration     | MiR-125b molecular sponge                                       | Muscle hypertrophy | [56,57] |
| Linc-smad7   | Nucleus/Cytoplasm | Inhibits proliferation, promotes differentiation and regeneration | MiR-30c molecular sponge                                       | Unknown        | [58,59]   |
| AK017368     | Cytoplasm         | Promotes proliferation, inhibits differentiation | MiR-715 expression Activates miR-715                            | Muscle hypertrophy | [60,61] |
| Yam1         | Nucleus/Cytoplasm | Regulates myogenesis                          | STAU1-mediated degradation of mRNA                              | Unknown        | [62]       |
| m1/2sbs-RNAs | Cytoplasm         | Promotes differentiation                      | Competitively binds to IMP2 protein                             | Unknown        | [63]       |
| LncMyoD      | Nucleus/Cytoplasm | Promotes differentiation                      | Interacts with ROCK1/YB-1                                        | Muscle atrophy | [58]       |
| Lnc-31       | Nucleus/Cytoplasm | Promotes proliferation, inhibits differentiation | Binds to SERCA and inhibits its activity                        | Unknown        | [65]       |
| Myoregulin   | SR/ER membrane    | Reduces muscle performance                    | Binds to SERCA and increases its activity                        | Unknown        | [66]       |
| DWORF        | SR membrane       | Improves muscle contraction capacity          | Promotes fusion and regeneration and muscle formation during embryogenesis | Interacts with Myomaker | Unknown |
| Myomixer     | Membrane          | Inhibits muscle regeneration                  | Interacts with the lysosomal v-ATPase                           | Unknown        | [68–71]   |
| LINC00961    | Endosome/Lysosome  | Promotes differentiation                      | Interacts with PR2 or KSRP, miR-let7 molecular sponge, encodes miR-675 | Unknown        | [72,73]   |
| H19          | Nucleus/Cytoplasm | Regulates differentiation and regeneration    | Interacts with PRC2 or KSRP                                    | Muscle hypertrophy | [51,74–79] |
| Sirt1 AS     | Nucleus/Cytoplasm | Promotes proliferation, inhibits differentiation | MiR-34a molecular sponge, stabilizes Sirt1 mRNA                | Unknown        | [80]       |
| LncIRIS1     | Nucleus/Cytoplasm | Promotes proliferation and differentiation    | MiR-15 molecular sponge                                         | Muscle atrophy | [81]       |
| LncMUMA      |                  | De-repressed muscle dystrophin mRNA isoforms  | Interacts with ASH1L protein                                    | Muscle atrophy | [82]       |
| DBE-T        | Nucleus           | Promotes muscle wasting                       | Interacts with ABIN-1                                           | Muscle atrophy | [83,84]   |
| Atroinc-1    | Nucleus           | Promotes muscle wasting                       | Interacts with ABIN-1                                           | Muscle atrophy | [85]       |
| Chornos      |                  | Inhibits muscle hypertrophy                   | Interacts with EZH2                                            | Muscle hypertrophy | [86]       |
which is induced by MyoD, recruits MyoD to myogenic marker gene promoters to activate their expression (e.g., Acta1) [2018]. Identified and characterized a new lncRNA, SYNPO2, whose promoter region can promote myoblast differentiation and proliferation [43]. Inhibition of Linc-RAM is achieved by recruiting the Suv39h1 protein to the binding site of MyoD, resulting in trimethylation of lysine 9 of histone 3 (H3K9me3) at the binding site, leading to H3K27me3 deposition [40]. Similarly, the Neat1 IncRNA modulates myogenesis by recruiting PRC2 to epigenetic-silenced target genes [14]. IncRNA Malat1, which was discovered in cancer cells, can promote the proliferation of cancer cells and tumor progression [91,92]. Malat1 regulates PRC2 to epigenetic-silenced target genes [14].

### 2.1. IncRNAs Regulate Chromosome Modification

IncRNA function is associated with their subcellular localization. Nuclear-retained IncRNAs play important roles in regulating gene transcription [35,87]. Nuclear IncRNAs can influence chromosome states by interacting with chromosome modification complexes, such as Polycomb Repressive Complex 2 (PRC2), and Switch/Sucrose nonfermentable (SWI/SNF) [88–90]. Some IncRNAs can regulate myogenesis by recruiting chromosome modification complexes to target gene promoters. Jin et al. (2018) identified and characterized a new IncRNA, SYNPO2, which is expressed from the MyoG gene and interacts with TAR DNA-binding protein 43 (TDP-43), a DNA/RNA-binding protein that regulates muscle-related gene expression (e.g., Acta1 and MyoD) [45].

An lncRNA called SYISL recruits PRC2 to the promoters of the target gene (e.g., p21, MyoG, or myh4), leading to H3K27me3 deposition [46]. Similarly, the Neat1 IncRNA modulates myogenesis by recruiting PRC2 to epigenetic-silenced target genes [14]. IncRNA Malat1, which was discovered in cancer cells, can promote the proliferation of cancer cells and tumor progression [91,92]. Malat1 regulates myoblast differentiation and muscle regeneration by recruiting the Suv39h1 protein to the binding site of MyoD, resulting in trimethylation of lysine 9 of histone 3 (H3K9me3) at the binding site, inhibiting myogenic gene expression [41]. Moreover, IncRNAs also regulate myogenesis by detaching chromosome modification complexes from target gene promoters. Linc-YY1 is transcribed upstream of the YY1 promoter and interacts with YY1. This interaction causes dissociation of the YY1/PRC2 complex from the promoters of the target gene, including miR-29, miR-1, MyHC, and Troponin, and reactivates their expression, promoting myoblast differentiation and regeneration [42].

### 2.2. IncRNAs Influence Transcription Activation

In addition to interacting with chromosome modification complexes, IncRNAs can also bind to transcription factors or RNA binding proteins to influence transcription activation. Linc-RAM, which is induced by MyoD, recruits MyoD to myogenic marker gene promoters to activate their transcription, thereby promoting muscle growth and regeneration [43]. Inhibition of Linc-RAM is essential for epidermal growth factor-related protein 2 (EGF2)-mediated suppression of myogenic differentiation [93]. An IncRNA called Myoline is muscle-enriched and accelerates myogenesis by regulating its neighboring protein-coding gene, Filip1, in cis, and interacting with TAR DNA-binding protein 43 (TDP-43), a DNA/RNA-binding protein that regulates muscle-related gene expression (e.g., Acta1 and MyoD) [45].

A lncRNA called Myoparr, which is expressed from the MyoG gene promoter region, can promote myoblast differentiation and inhibit myoblast proliferation. Myoparr...
is essential for increasing the interaction between Ddx17 and PCAF, and promotes binding of the Ddx17/PCAF complex to the MyoG promoter; then, it recruits Pol II to the MyoG promoter to further promote MyoG transcription and myoblast differentiation [46]. IncRNA Irm is upregulated upon myoblast differentiation and promotes myogenic differentiation and regeneration by directly binding to MEF2D and promoting the assembly of MyoD/MEF2D on the regulatory elements of target genes [47].

Enhancer RNAs (eRNAs) are a large class of lncRNAs that are transcribed from known DNA enhancer regions, and play important roles in transcriptional activation of neighboring genes by recruiting core transcription factors or accelerating the interaction between enhancers and promoters [94, 95]. The myogenic eRNA MyoD upstream noncoding RNA (MUNC), also known as DRR eRNA, is reported to promote myoblast differentiation through at least two different mechanisms. First, MUNC acts as a typical eRNA to induce MyoD expression in cis. Second, MUNC can also act as an atypical eRNA to regulate MyoG, Myh3, and many other myogenic genes [48, 49].

2.3. IncRNAs Serve as miRNA Molecular Sponges

The expression of lncRNA is highly associated with miRNA, suggesting that lncRNAs and miRNAs have co-regulatory functions in biological processes [96–98]. A lncRNA can act as a miRNA molecular sponge and weaken the inhibitory effects of miRNAs on target genes [99]. Many lncRNAs have been reported to regulate myogenesis by functioning as molecular sponges for miRNAs.

Linc-MD1 exhibits tissue-specific expression in skeletal muscle, and can promote the differentiation of skeletal muscle cells. During myogenic differentiation, linc-MD1 serves as a molecular sponge of miR-133 and miR-135 to attenuate the repression of their target genes, MAML1 and MEF2C. This increases MAML1 and MEF2C expression, thus promoting the differentiation of skeletal muscle [53]. LncRNA MAR1 is also highly expressed in muscle; overexpression of MAR1 can significantly promote myogenic differentiation and muscle growth. MAR1 can serve as a molecular sponge of miR-487b, weakening the effects of miR-487b upon its target gene, Wnt5a, and thereby promoting myogenic differentiation [54]. Lnc-mg is induced during myogenic differentiation and promotes myogenic differentiation and muscle regeneration by sponging miR-125b [56]. Lnc-mg can also regulate the expression of miR-351-5p, which can regulate myogenesis by targeting beta lactamase [57]. Linc-smad7 is a transcript of lncRNA-smad7 which has been reported to repress breast cancer cell apoptosis [100]. A transcriptome analysis of C2C12 cells demonstrated that Linc-smad7 is upregulated upon myoblast differentiation [58]. Overexpression of Linc-smad7 inhibits myoblast proliferation but promotes myoblast differentiation and regeneration. Linc-smad7 interacts with miR-125b and weakens the inhibitory effects of miR-125b upon its target genes, IGF2 and smad7 [59]. The lncRNA AK017368 promotes myoblast proliferation but inhibits myoblast differentiation by acting as a competing endogenous RNA of miR-30c [60, 61].

2.4. IncRNAs Function at Post-Transcriptional Levels

Cytoplasm-located lncRNAs can regulate the expression of target genes at the post-transcriptional level by affecting the stability, splicing, and translation of mRNAs and the stability of proteins [101]. m1/2sbs-RNA is a type of lncRNA containing several SINE sequences that can complement genes containing the same SINE sequences, such as Cdc6 and Traf6. It forms a STA1-binding site (SBS), which leads to STA1-mediated degradation of mRNA [63]. In addition to affecting the stability of mRNA, lncRNA can also regulate mRNA translation. LncMyoD, transcribed from the upstream region of the MyoD gene, can competitively bind the IMP2 protein. This reduces the binding ability of IMP2 for the target genes, c-Myc and N-Ras, inhibiting their translation and promoting cell differentiation [58]. Lnc-31 is a cytoplasmic long noncoding RNA that is downregulated during myoblast differentiation. Knockdown of lnc-31 expression inhibits myoblast proliferation but enhances myoblast differentiation [64]. Lnc-31 affects myogenesis by binding both Rock1 (a known myogenesis suppressor) mRNA and YB-1 (a translational regulator) protein, and promotes the positive effects of YB-1 on Rock1 translation activation [65].
2.5. IncRNAs Encode Micropeptides

Although IncRNAs have little protein coding ability compared to mRNAs, some IncRNAs can give rise to functional micropeptides [102–105]. IncRNA-Six1 is located in the upstream of the protein-coding gene Six1, and has a role in promoting chicken skeletal muscle growth by regulating Six1 in cis. IncRNA-Six1 can produce a 7.26 kDa micropeptide, which plays an important role in IncRNA-Six1 cis-acting regulation of Six1 [106]. Myoregulin (MLN) is a conserved micropeptide encoded by a skeletal muscle-specific putative IncRNA, and its expression is regulated by MyoD and MEF2. MLN binds directly to sarco-endoplasmic reticulum Ca^{2+} adenosine triphosphatase (SERCA), inhibiting SERCA activity and hindering the uptake of Ca^{2+} into the sarcoplasmic reticulum. Genetic deletion of MLN increases Ca^{2+} release in skeletal muscle, and improves muscle performance [66]. DWORF is a micropeptide of 34 amino acids encoded by a putative IncRNA that is specifically expressed in the heart and soleus. In mice, DWORF interacts with SERCA and increases SERCA activity, affecting muscle contraction. Knockout of DWORF in slow skeletal muscle leads to delayed Ca^{2+} release and reduced SERCA activity [67]. Myomixer, also named Minion [70] and Myomerger [68], is an 84-amino acid muscle-specific micropeptide that interacts with Myomaker to promote cell fusion and skeletal muscle formation during embryogenesis [69]. A recent study demonstrated that Myomixer is also required for muscle regeneration [71]. The small regulatory polypeptide of amino acid response (SPAR) is encoded by the conserved IncRNA LINC00961. SPAR is located in the late endosome/lysosome and negatively regulates mTORC1 activation by binding to lysosomal v-ATPase in mammals. LINC00961 is highly expressed in skeletal muscle and is downregulated upon acute injury by CTX injection. Knocking out SPAR expression in mice while maintaining host IncRNA expression using CRISPR/Cas9 engineering significantly increases muscle regeneration after CTX injection by activating mTORC1, which has a positive effect on satellite cell proliferation, differentiation, and myofiber maturation [72,73].

Many IncRNAs have been shown to regulate myogenesis via multiple mechanisms. H19 can inhibit myoblast differentiation by recruiting PRC2 to the promoters of target genes [51,107,108], by serving as a molecular sponge of miRNA let-7 [74], or by recruiting KSRP protein to the 3′ end of MyoG mRNA to decrease the stability of MyoG mRNA [75]. Furthermore, H19 promotes muscle regeneration by producing two conserved miRNAs, miR-675-3p and miR-675-5p [76]. Another IncRNA, Sirt1 AS IncRNA, which is transcribed from the Sirt1 antisense strand, accelerates myoblast proliferation and represses myoblast differentiation by attenuating the inhibition of miR-34a to Sirt1 translation, and enhancing the stability of Sirt1 mRNA [80].

3. IncRNAs in Skeletal Muscle Disease

Alterations in myogenesis and muscle regeneration may lead to numerous muscle diseases, such as sarcopenia, muscle hypertrophy, and muscular dystrophy. The abnormal expression of IncRNAs is associated with various muscle diseases, and rescue of their normal expression levels in skeletal muscle can alleviate the disease phenotype (Figure 2). Here, we have summarized the latest progress on IncRNAs in human muscle disease and animal muscular disease models.

3.1. IncRNAs in Human Skeletal Muscle Disease

Duchenne muscular dystrophy (DMD) is one of the most common and serious forms of muscular dystrophy, and is caused by losing functional dystrophin protein [109]. The DMD locus harbors multiple IncRNAs, and these IncRNAs repress the expression of the dystrophin mRNA isoforms through interacting with the dystrophin promoter [110]. Several IncRNAs exhibit expression changes in skeletal muscles in DMD patients relative to normal people. For example, Inc-31 is up-regulated in the skeletal muscles of DMD patients [64]. Linc-MD1 is down-regulated in myoblasts derived from muscles of DMD patients [53]. The myoblasts from DMD patients exhibit impaired cell differentiation, suggesting that the aberrant expression of Inc-31 and linc-MD1 is associated with DMD disease.
Cells 2019, 8, x FOR PEER REVIEW 7 of 20

Figure 2. Functional IncRNAs involved in skeletal muscle disease.

Facioscapulohumeral muscular dystrophy (FSHD) is the third most prevalent muscular dystrophy type, and results in progressive weakness and loss of skeletal muscles [111,112]. FSHD is linked to a reduction in the copy number of the 3.3 kb D4Z4 repeat mapping to 4q35, but is not associated with a classical mutation within a protein-coding gene. In FSHD patients, IncRNA DBE-T interacts with the Trithorax group protein Ash1L and recruits it to the FSHD gene locus, leading to H3K36me2 and de-repression of FSHD genes, and thus promoting FSHD pathogenesis [83].

The clinical symptoms of idiopathic inflammatory myopathies (IIM) include muscle weakness and inflammation (myositis). Next generation sequencing was employed to examine the transcriptome in muscle biopsies obtained from two histologically distinct patient populations: body myositis (IBM) patients and anti-Jo-1-associated myositis (Jo-1) patients. The results showed that 55 and 46 lncRNAs are differentially expressed in IBM and Jo-1 myositis patients compared to controls, respectively. Of these lncRNAs, 16 lncRNAs, including H19, IncMyoD and MALAT1, are differentially expressed in both IBM and Jo-1 myositis patients. These differentially expressed lncRNA may be involved in myositis [113].

3.2. LncRNAs in Skeletal Muscle Disease Models

3.2.1. LncRNAs in Muscle Atrophy

Muscular dystrophy is the most common muscle disorder in humans, and is accompanied by muscle weakness and muscle wasting [114]. Several lncRNAs are differentially expressed between muscle dystrophy patients and normal individuals, including linc-MD1, Inc-31, Atrolnc-1, LncIRS1, and MAR1 [53,54,64,81,85]. Compared to normal cells, linc-MD1 expression levels are strongly reduced in Duchenne muscular dystrophy (DMD) myoblasts. Following overexpression of linc-MD1 in DMD myoblasts, the expression levels of MyoG, MyoHC, MEF2C and MAML1 return to normal [53].

Chronic kidney disease is commonly associated with cachexia, and causes skeletal muscle wasting. Sun et al. (2018) found that the expression of eight lncRNAs simultaneously increased in atrophying muscles in three mouse catabolic models, and nine lncRNAs were downregulated in atrophying muscles. One of the identified lncRNAs, Atrolnc-1, is abundantly expressed in skeletal muscle and its expression is markedly increased in atrophying muscles. Overexpression of Atrolnc-1 in muscle causes myofiber atrophy, while inhibition of Atrolnc-1 ameliorates muscle wasting in mice. Mechanistically, Atrolnc-1 strongly binds to ABIN-1, inhibiting NF-κB signaling and causing protein degradation in muscle cells [85].

LncIRS1 has also been identified as a regulator of muscle development, and can promote myogenic differentiation, muscle mass, and muscle cross-sectional area via sponging the miR-15 family to activate the IGF1-P13K/AKT pathway. Importantly, in a dexamethasone-induced myotube atrophy model in vitro, LncIRS1 regulated the expression of muscle atrophy-related genes such as p-Foxo1, p-Foxo3,
p-Foxo4, p-AKT, and Atrogin-1, and rescued dexamethasone-induced muscle atrophy in cultured myotubes [81].

The lncRNA MAR1 has been found to be downregulated in aged mice and mechanically unloaded mice. Enforced MAR1 expression attenuates muscle atrophy in mouse models of age-related muscle atrophy and mechanical unloading-induced muscle atrophy, suggesting that MAR1 could be a novel therapeutic target for treating muscle atrophy induced by aging or mechanical unloading [54]. MAR1 also affects myogenesis by enhancing Wnt5a function [54]. Wnt5a may contribute to age-related skeletal muscle atrophy in rats [55]. These studies suggest that MAR1 may be involved in the Wnt5a-regulated muscular atrophy pathway.

Another atrophy-related lncRNA, mechanical unloading-induced muscle atrophy-related lncRNA (lncMUMA), is the most downregulated lncRNA during muscle atrophy development in hindlimb suspension mice. LncMUMA promotes myogenesis by acting as an miR-762 molecular sponge to regulate MyoD expression. Therapeutically, the enforced expression of lncMUMA prevents muscle atrophy development and reverses established skeletal muscle atrophy following mechanical unloading [82].

The lncRNA Myoparr is transcribed from the upstream domain of the MyoG promoter, and promotes myogenic differentiation by regulating the association between Ddx17 and the histone acetyltransferase PCAF. Overexpression of Myoparr also promotes skeletal muscle atrophy caused by denervation, and knockdown of Myoparr rescues muscle wasting, suggesting that Myoparr may be a potential therapeutic target for neurogenic atrophy [46].

### 3.2.2. IncRNAs in Muscle Hypertrophy

Muscle hypertrophy is associated with increased intracellular RNA and protein synthesis, and decreased protein degradation. The balance between protein synthesis and degradation is regulated by many pathways and regulators, such as the mTOR, IGF, and AMPK pathways, myostatin, and myogenic regulatory factors [115–118]. In addition, muscle hypertrophy requires activation of satellite cells [119,120]. Recent studies have indicated that several lncRNAs, such as H19, Chronos, Inc-mg and AK017368, are associated with muscle hypertrophy [56,60,77,79,87].

H19 is one of the earliest known examples of imprinted lncRNA, and plays a prominent role in regulating myogenic differentiation, which is fully repressed after birth except in skeletal muscle [77,121]. Deletion or mutation of H19 (H19Δ3) results in muscle hypertrophy and hyperplasia via reactivation of the imprinted gene network, particularly IGF2 upregulation following H19 deletion. Moreover, loss-of-function of H19 decreases myostatin (Mstn) expression [77–79]. These results suggest that H19 regulates muscle hypertrophy and hyperplasia mainly by influencing IGF2 and Mstn expression.

The Bmp7 signaling pathway positively regulates skeletal muscle hypertrophy through activation of Smad1/5 [122]. The muscle-enriched lncRNA Chronos is negatively regulated by Akt signaling and positively correlated with advancing age. Chronos epigenetically inhibits the expression of Bmp7 by recruiting EZH2. Knockdown of Chronos significantly increases the cross-sectional area of myofibers, and results in muscle hypertrophy in vivo [86].

### 4. Identification of IncRNAs in Agricultural Animal Meat Production

Muscle growth rate and muscle mass are two economically important traits in agricultural animal production. Compared with IncRNAs in model animals, the functions and mechanisms of IncRNAs affecting animal production are relatively unknown, although thousands of IncRNAs have been identified in livestock and poultry muscle (Table 2).
Table 2. LncRNAs involved in agriculture animal muscle development.

| LncRNA  | Location          | Function                                                                 | Mechanism                  | Ref.        |
|---------|-------------------|--------------------------------------------------------------------------|-----------------------------|-------------|
| MEG3    | Mainly in cytoplasm | Promotes bovine myoblast differentiation; involved in pig meat production traits | MiR-135 molecular sponge    | [123,124]   |
| LncMD   | Mainly in nucleus  | Promotes bovine myoblast differentiation                                | MiR-125b molecular sponge   | [125]       |
| Lnc133b | Mainly in nucleus  | Regulates bovine skeletal muscle satellite cell proliferation and differentiation | MiR-133b molecular sponge   | [126]       |
| MDNCR   | Nucleus/Cytoplasm  | Promotes bovine myoblast differentiation, inhibits cell proliferation    | Represses Sirt1/FoxO1       | [128]       |
| H19     | Nucleus/Cytoplasm  | Promotes bovine skeletal muscle satellite cell differentiation            |                             | [129]       |
| YYW     | Mainly in nucleus  | Promotes bovine myoblast proliferation and differentiation               |                             | [130]       |
| LncKBTBD10 | Mainly in nucleus | Involved in bovine skeletal satellite cell proliferation and differentiation |                             | [131]       |
| Lnc-SEMT| Nucleus/Cytoplasm  | Promotes sheep myoblast differentiation and muscle growth                 | MiR-125b molecular sponge   | [132]       |
| LncRNA-Six1 | Nucleus/Cytoplasm | Promotes chicken myoblast proliferation and differentiation, and involved in skeletal muscle fiber types transformation | MiR-1611 molecular sponge   | [133]       |
| LncIRS1 | Nucleus/Cytoplasm  | Promotes the proliferation and differentiation of chicken myoblast      | MiR-15 molecular sponge     | [81]        |

4.1. IncRNAs in Pig Skeletal Muscle Development

Tens of thousands of IncRNAs have been detected in the porcine genome through RNA sequencing (RNA-seq) and other technologies [133,134], most of which have been involved in pig skeletal muscle development [135–140]. Ren et al. (2009) isolated and identified the first pig IncRNA, trophoblast-derived noncoding RNA (TncRNA), which is differentially expressed in skeletal muscle in 90-day embryos of Tongcheng and Landrace pigs [139]. Zhao et al. (2015) identified more than 570 IncRNAs by systematically analyzing IncRNA expression in skeletal muscle at different times, and found an IncRNA, CUFF.8631, that is conserved among humans, mice, and pigs. This IncRNA contains four transcripts, and the transcripts CUFF.8631.1 and CUFF.8631.3 are differentially expressed during muscle development, suggesting that they may play a role in this process [140]. LncRNA MEG3 is differentially expressed in postnatal skeletal muscle development and conserved among humans, mice, and pigs. Four single nucleotide polymorphisms of MEG3 have been identified in Large White pigs and are associated with meat-producing traits [124].

4.2. IncRNAs in Bovine Skeletal Muscle Development

About 8000 IncRNAs expressed in bovine muscle have been identified and analyzed [141–143]. Several IncRNAs have been reported to play important roles in bovine myoblast proliferation and differentiation. For example, LncMD promotes bovine myoblast differentiation by acting as a molecular sponge of miR-125b [125]. Lnc133b regulates bovine skeletal muscle satellite cell proliferation and differentiation by sponging miR-133b [126]. LncRNA MDNCR promotes bovine myoblast differentiation but inhibits proliferation by acting as a molecular sponge of miR-133a, and thus weakens the inhibitory effects of miR-133a upon its target gene, GosB [127]. LncRNA H19 promotes bovine skeletal muscle satellite cell differentiation by repressing Sirt1/FoxO1 [128]. LncRNA MEG3 has a
functional role in promoting bovine skeletal differentiation by sponging miR-135, attenuating the suppressive effects of miR-135 upon MEF2C [123]. LncRNA YYW is highly expressed in muscle, and promotes bovine myoblast proliferation and differentiation [129]. The LncRNA lncKBTBD10 is also induced during myogenic differentiation and plays a role in bovine skeletal muscle myogenesis [130].

4.3. IncRNAs in Sheep and Goat Skeletal Muscle Development

Zhan et al. (2016) identified 3981 IncRNAs in goat muscle tissues at different embryonic stages and three days after birth by RNA-seq, of which 577 IncRNAs were differentially expressed among the different stages of muscle development [144]. Ren et al. (2017) used Ribo-Zero RNA-seq technology to analyze the muscle IncRNA of Hu sheep at the fetal, lamb, and adult stages, and identified 6924 differentially expressed IncRNAs. GO analysis revealed that these differentially expressed IncRNAs are involved in muscle development and organ formation [145]. Li et al. (2019) identified 404 differentially expressed IncRNAs in sheep muscle from the prenatal to postnatal developmental stages using RNA-seq [146]. Lnc-SEMT, which is specifically expressed in muscle, can regulate IGF2 expression by sponging miR-125b, thus promoting muscle growth and development. Lnc-SEMT transgenic sheep exhibit significant muscle hypertrophy and weight gain [131].

4.4. IncRNAs in Chicken Skeletal Muscle Development

A total of 8072 chicken skeletal muscle-related IncRNAs have been detected by RNA-seq [147–151]. Among them, IncRNA-Six1 has a functional role in regulating chicken muscle development by sponging miRNA [132], and by encoding a micropeptide [106]. Another IncRNA, lncIRS1, is involved in regulating chicken muscle atrophy by acting as a molecular sponge for the miR-15 family to activate the IGF1-PI3K/AKT pathway [81].

5. Challenges and Future Perspectives

All of the above studies have shown that IncRNAs regulate multiple aspects of skeletal muscle development and disease by various regulatory mechanisms. Although the functions and mechanisms of some IncRNAs have been clearly studied, the research of IncRNAs in skeletal muscle is far from complete. Current studies regarding IncRNAs in muscles mainly focus on their roles in muscle atrophy and hypertrophy, muscle growth, and development after birth. Further attention should be paid to the regulation of muscle development during the embryonic stage, conversion of different types of muscle fibers, muscle aging, muscle metabolism, and muscle tumors. In addition, due to large number of IncRNA transcripts and low sequence conservation, the functions and mechanisms of IncRNAs are more complex than those of protein-coding genes. Therefore, there are still many unsolved problems and challenges ahead, including the following:

i. As tens of thousands of IncRNAs have been identified in muscles, their functions should be further explored by high-throughput methods. Recently, the development of genome editing techniques such as CRISPR/Cas9 system has provided powerful tools to identify functional IncRNAs in vivo and in vitro [152–154]. Thus, construction of sgRNA library targeting IncRNAs and establishment of efficient screening systems for muscle cells will be beneficial to the screening of key functional IncRNAs in skeletal muscles.

ii. Continual innovation in data analysis tools has accelerated the investigation and identification of IncRNAs in myogenesis [155]. The development of computer models and algorithms provides an important basis for the functional prediction of IncRNAs [156–159]. Several databases, such as LncATLAS, starBase v2.0, CatRAPID, and RPISeq, have been established to predict the functions of IncRNAs, such as subcellular location, binding proteins, and miRNAs [160–163]. The computer aided functional characterizations of IncRNAs need to be further verified by experiments, as computer model-assisted predictions are mainly based on probability and statistics. Moreover, the annotation information in these databases is still incomplete, especially
information relating to different transcripts. Non-poly (A) or other forms of lncRNAs, such as sno lncRNAs, are often ignored, as RNA-seq technology is mainly based on poly (A) sequencing techniques. Therefore, developing more advanced RNA-seq technologies and corresponding analysis tools will help us to recognize lncRNAs more comprehensively.

iii. lncRNAs can play regulatory roles by interacting with DNA, RNA and proteins, and systematic identification of molecules interacting with lncRNAs is essential to elucidating their molecular mechanisms of action. Thus, more efficient techniques such as ChiRP (Chromatin isolation by RNA purification) and dChiRP (domain-specific ChiRP) should be further developed to study lncRNA interactomes.

iv. lncRNAs can serve as biomarkers and therapeutic targets of several diseases, such as cancer, cardiopathy, neurologic diseases, and immunological diseases [164–168]. However, few lncRNAs have been identified and used as therapeutic targets for skeletal muscle diseases. Therefore, identifying more key lncRNAs related to skeletal muscle diseases will contribute to the treatment of skeletal muscle diseases in the future.

In this review, we presented the latest advances in the regulation network of lncRNAs in skeletal muscle development and muscle diseases, as well as the recent progress in agricultural animal meat production. Moreover, challenges and future perspectives were also discussed in the identification of novel muscle-related lncRNAs. Since the methods of studying lncRNAs have been reviewed in many studies, this review does not cover this aspect in much detail. In summary, lncRNAs play key roles in muscle development and regeneration, and in muscle diseases. The development of new tools and technologies will enable more functional lncRNAs to be identified in the future. Further studies will help to achieve an in-depth understanding of the functions and mechanisms of lncRNAs, and ultimately lead to the application of lncRNAs as therapeutic targets for muscle diseases or biomarkers for animal production.

Funding: This work was financially supported by the Natural Science Foundation of Hubei Province (Grant No. 2018CFA015), the Fundamental Research Funds for the Central Universities (Program No. 2662018PY037, 2662018PY045), the National Key Project for Transgenic Grant Nos. 2016ZX08006-002 and 2018ZX08010-12B, the Agricultural Innovation Fund of Hubei Province (2016-620-000-001-043), and the China Postdoctoral Science Foundation (Program No. 590319103).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Giordani, L.; He, G.J.; Negroni, E.; Sakai, H.; Law, J.Y.C.; Siu, M.M.; Wan, R.; Corneau, A.; Tajbakhsh, S.; Cheung, T.H.; et al. High-Dimensional Single-Cell Cartography Reveals Novel Skeletal Muscle-Resident Cell Populations. Mol. Cell 2019, 74, 609–621.e6. [CrossRef]

2. Musumeci, G.; Castrogiovanni, P.; Coleman, R.; Szychlinska, M.A.; Salvatorelli, L.; Parenti, R.; Magro, G.; Imbesi, R. Somitogenesis: From somite to skeletal muscle. Acta Histochem. 2015, 117, 313–328. [CrossRef]

3. Maroto, M.; Reshef, R.; Munsterberg, A.E.; Koester, S.; Goulding, M.; Lassar, A.B. Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 1997, 89, 139–148. [CrossRef]

4. Buckingham, M.; Relaix, F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu. Rev. Cell Dev. Biol. 2007, 23, 645–673. [CrossRef]

5. Lagha, M.; Kormish, J.D.; Rocancourt, D.; Manceau, M.; Epstein, J.A.; Zaret, K.S.; Relaix, F.; Buckingham, M.E. Pax3 regulation of FGF signaling affects the progression of embryonic progenitor cells into the myogenic program. Genes Dev. 2008, 22, 1828–1837. [CrossRef]

6. Collins, C.A.; Gnocchi, V.F.; White, R.B.; Boldrin, L.; Perez-Ruiz, A.; Relaix, F.; Morgan, J.E.; Zammit, P.S. Integrated functions of Pax3 and Pax7 in the regulation of proliferation, cell size and myogenic differentiation. PLoS ONE 2009, 4, e4475. [CrossRef]

7. Braun, T.; Gautel, M. Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat. Rev. Mol. Cell Biol. 2011, 12, 349–361. [CrossRef]
8. Buckingham, M. Myogenic progenitor cells and skeletal myogenesis in vertebrates. *Curr. Opin. Genet. Dev.* 2006, 16, 525–532. [CrossRef]
9. Buckingham, M.; Rigby, P.W. Gene regulatory networks and transcriptional mechanisms that control myogenesis. *Dev. Cell* 2014, 28, 225–238. [CrossRef]
10. Bentzinger, C.F.; Wang, Y.X.; Rudnicki, M.A. Building muscle: Molecular regulation of myogenesis. *Cold Spring Harb. Perspect. Biol.* 2012, 4. [CrossRef]
11. Tapscott, S.J.; Davis, R.L.; Thayer, M.J.; Cheng, P.F.; Weintraub, H.; Lassar, A.B. MyoD1: A nuclear phosphoprotein requiring a Myc homology region to convert fibroblasts to myoblasts. *Science* 1988, 242, 405–411. [CrossRef] [PubMed]
12. Choi, J.; Costa, M.L.; Mermelstein, C.S.; Chagas, C.; Holtzer, S.; Holtzer, H. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. *Proc. Natl. Acad. Sci. USA* 1990, 87, 7988–7992. [CrossRef] [PubMed]
13. Mastroyiannopoulos, N.P.; Nicolaou, P.; Anayasa, M.; Uney, J.B.; Phylactou, L.A. Down-regulation of myogenin can reverse terminal muscle cell differentiation. *PLoS ONE* 2012, 7, e29896. [CrossRef] [PubMed]
14. Wang, S.; Zuо, H.; Jin, J.; Lv, W.; Xu, Z.; Fan, Y.; Zhang, J.; Zuo, B. Long noncoding RNA Neat1 modulates myogenesis by recruiting Ezh2. *Cell Death Dis.* 2019, 10, 505. [CrossRef] [PubMed]
15. Barreiro, E.; Tajbakhsh, S. Epigenetic regulation of muscle development. *J. Muscle Res. Cell Motil.* 2017, 38, 31–35. [CrossRef] [PubMed]
16. Bharathy, N.; Ling, B.M.; Taneja, R. Epigenetic regulation of skeletal muscle development and differentiation. *Subcell. Biochem.* 2013, 61, 139–150. [CrossRef] [PubMed]
17. Brand-Saberi, B. Genetic and epigenetic control of skeletal muscle development. *Ann. Anat.* 2005, 187, 199–207. [CrossRef]
18. Brand-Saberi, B.; Christ, B. Genetic and epigenetic control of muscle development in vertebrates. *Cell Tissue Res.* 1999, 296, 199–212. [CrossRef]
19. Jin, W.; Peng, J.; Jiang, S. The epigenetic regulation of embryonic myogenesis and adult muscle regeneration by histone methylation modification. *Biochem. Biophys. Rep.* 2016, 6, 209–219. [CrossRef]
20. Relaix, F.; Zammit, P.S. Satellite cells are essential for skeletal muscle regeneration: The cell on the edge returns centre stage. *Development* 2012, 139, 2845–2856. [CrossRef]
21. Persson, P.B. Skeletal muscle satellite cells as myogenic progenitors for muscle homeostasis, growth, regeneration and repair. *Acta Physiol.* (Oxf.) 2015, 213, 537–558. [CrossRef] [PubMed]
22. Dumont, N.A.; Bentzinger, C.F.; Sincennes, M.C.; Rudnicki, M.A. Satellite Cells and Skeletal Muscle Regeneration. *Compr. Physiol.* 2015, 5, 1027–1059. [CrossRef] [PubMed]
23. Sambasivan, R.; Yao, R.; Kissenpfennig, A.; Van Wittenbergh, L.; Paldi, A.; Gayraud-Morel, B.; Guenou, H.; Malissen, B.; Tajbakhsh, S.; Galy, A. Pax7-expressing satellite cells are indispensable for adult skeletal muscle regeneration. *Development* 2011, 138, 3647–3656. [CrossRef] [PubMed]
24. Tidball, J.G. Regulation of muscle growth and regeneration by the immune system. *Nat. Rev. Immunol.* 2017, 17, 165–178. [CrossRef] [PubMed]
25. Endo, T. Molecular mechanisms of skeletal muscle development, regeneration, and osteogenic conversion. *Bone* 2015, 80, 2–13. [CrossRef] [PubMed]
26. Kapranov, P.; Cheng, J.; Dike, S.; Nix, D.A.; Duttagupta, R.; Willingham, A.T.; Stadler, P.F.; Hertel, J.; Hackermuller, J.; Hofacker, I.L.; et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. *Science* 2007, 316, 1484–1488. [CrossRef]
27. Wilusz, J.E.; Sunwoo, H.; Spector, D.L. Long noncoding RNAs: Functional surprises from the RNA world. *Genes Dev.* 2009, 23, 1494–1504. [CrossRef] [PubMed]
28. Cabili, M.N.; Trapnell, C.; Goff, L.; Koziol, M.; Tazon-Vega, B.; Regev, A.; Rinn, J.L. Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. *Genes Dev.* 2011, 25, 1915–1927. [CrossRef]
29. Jia, H.; Osak, M.; Bogu, G.K.; Stanton, L.W.; Johnson, R.; Lipovich, L. Genome-wide computational identification and manual annotation of human long noncoding RNA genes. *RNA* 2010, 16, 1478–1487. [CrossRef]
30. Clark, M.B.; Johnston, R.L.; Inostroza-Ponta, M.; Fox, A.H.; Fortini, E.; Moscato, P.; Dinger, M.E.; Mattick, J.S. Genome-wide analysis of long noncoding RNA stability. *Genome Res.* 2012, 22, 885–898. [CrossRef]
31. Derrien, T.; Johnson, R.; Bussotti, G.; Tanzer, A.; Djebali, S.; Tilgner, H.; Guernec, G.; Martin, D.; Merkel, A.; Knowles, D.G.; et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res. 2012, 22, 1775–1789. [CrossRef] [PubMed]

32. Yao, R.W.; Wang, Y.; Chen, L.L. Cellular functions of long noncoding RNAs. Nat. Cell Biol. 2019, 21, 542–551. [CrossRef] [PubMed]

33. Chen, L.L. Linking Long Noncoding RNA Localization and Function. Trends Biochem. Sci. 2016, 41, 761–772. [CrossRef] [PubMed]

34. Flynn, R.A.; Chang, H.Y. Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell 2014, 14, 752–761. [CrossRef] [PubMed]

35. Guttman, M.; Donaghey, J.; Carey, B.W.; Garber, M.; Grenier, J.K.; Munson, G.; Young, G.; Lucas, A.B.; Ach, R.; Bruhn, L.; et al. lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature 2011, 477, 295–305. [CrossRef]

36. Satpathy, A.T.; Chang, H.Y. Long noncoding RNA in hematopoiesis and immunity. Immunity 2015, 42, 792–804. [CrossRef]

37. Jandura, A.; Krause, H.M. The New RNA World: Growing Evidence for Long Noncoding RNA Functionality. Trends Genet. 2017, 33, 665–676. [CrossRef]

38. Schmitt, A.M.; Chang, H.Y. Long Noncoding RNAs in Cancer Pathways. Cancer Cell 2016, 29, 452–463. [CrossRef]

39. Li, Y.; Chen, X.; Sun, H.; Wang, H. Long non-coding RNAs in the regulation of skeletal myogenesis and muscle diseases. Cancer Lett. 2018, 417, 58–64. [CrossRef]

40. Jin, J.J.; Lv, W.; Xia, P.; Xu, Z.Y.; Zheng, A.D.; Wang, X.J.; Wang, S.S.; Zeng, R.; Luo, H.M.; Li, G.L.; et al. Long noncoding RNA SYISL regulates myogenesis by interacting with polycomb repressive complex 2. Proc. Natl. Acad. Sci. USA 2018, 115, E9802–E9811. [CrossRef]

41. Chen, X.; He, L.; Zhao, Y.; Li, Y.; Zhang, S.; Sun, K.; So, K.; Chen, F.; Zhou, L.; Lu, L.; et al. Malat1 regulates myogenic differentiation and muscle regeneration through modulating MyoD transcriptional activity. Cell Discov. 2017, 3, 17002. [CrossRef] [PubMed]

42. Zhou, L.; Sun, K.; Zhao, Y.; Zhang, S.; Wang, X.; Li, Y.; Lu, L.; Chen, X.; Chen, F.; Bao, X.; et al. Linc-YY1 promotes myogenic differentiation and muscle regeneration through an interaction with the transcription factor YY1. Nat. Commun. 2015, 6, 10026. [CrossRef] [PubMed]

43. Yu, X.; Zhang, Y.; Li, T.; Ma, Z.; Jia, H.; Chen, Q.; Zhao, Y.; Zhai, L.; Zhong, R.; Li, C.; et al. Long non-coding RNA Linc-RAM enhances myogenic differentiation by interacting with MyoD. Nat. Commun. 2017, 8, 14016. [CrossRef] [PubMed]

44. Wang, L.; Zhao, Y.; Bao, X.; Zhu, X.; Kwok, Y.K.; Sun, K.; Chen, X.; Huang, Y.; Jauch, R.; Esteban, M.A.; et al. LncRNA Dum interacts with Dnmts to regulate Dppa2 expression during myogenic differentiation and muscle regeneration. Cell Res. 2015, 25, 335–350. [CrossRef] [PubMed]

45. Militello, G.; Hosen, M.R.; Ponnamoreva, Y.; Gellert, P.; Weirick, T.; John, D.; Hindi, S.M.; Mamchaoui, K.; Mouly, V.; Doring, C.; et al. A novel long non-coding RNA Myolinc regulates myogenesis through TDP-43 and Filip1. J. Mol. Cell Biol. 2018, 10, 102–117. [CrossRef] [PubMed]

46. Hitachi, K.; Nakatani, M.; Takasaki, A.; Ouchi, Y.; Uezumi, A.; Ageta, H.; Inagaki, H.; Kurahashi, H.; Tsuchida, K. Myogenin promoter-associated IncRNA Myoparr is essential for myogenic differentiation. EMBO Rep. 2019, 20, 18. [CrossRef]

47. Sui, Y.; Han, Y.; Zhao, X.; Li, D.; Li, G. Long non-coding RNA Irm enhances myogenic differentiation by interacting with MEF2D. Cell Death Dis. 2019, 10, 181. [CrossRef]

48. Cichewicz, M.A.; Kiran, M.; Przanowska, R.K.; Sobierajska, E.; Shibata, Y.; Dutta, A. MUNC, an Enhancer RNA Upstream from the MYOD Gene, Induces a Subgroup of Myogenic Transcripts in trans Independently of MyoD. Mol. Cell Biol. 2018, 38. [CrossRef] [PubMed]

49. Mueller, A.C.; Cichewicz, M.A.; Dey, B.K.; Layer, R.; Reon, B.J.; Gagan, J.R.; Dutta, A. MUNC, a long noncoding RNA that facilitates the function of MyoD in skeletal myogenesis. Mol. Cell Biol. 2015, 35, 498–513. [CrossRef]

50. Zhou, Y.; Cheunsuchon, P.; Nakayama, Y.; Lawlor, M.W.; Zhong, Y.; Rice, K.A.; Zhang, L.; Zhang, X.; Gordon, F.E.; Lidov, H.G.; et al. Activation of paternally expressed genes and perinatal death caused by deletion of the Gtl2 gene. Development 2010, 137, 2643–2652. [CrossRef]
51. Zhao, J.; Ohsumi, T.K.; Kung, J.T.; Ogawa, Y.; Grau, D.J.; Sarma, K.; Song, J.J.; Kingston, R.E.; Borowsky, M.; Lee, J.T. Genome-wide identification of polycomb-associated RNAs by RIP-seq. *Mol. Cell* **2010**, *40*, 939–953. [CrossRef] [PubMed]

52. Caretti, G.; Schiltz, R.L.; Dilworth, F.J.; Di Padova, M.; Zhao, P.; Ogryzko, V.; Fuller-Pace, F.V.; Hoffman, E.P.; Tapscott, S.J.; Sartorelli, V. The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. *Dev. Cell* **2006**, *11*, 547–560. [CrossRef] [PubMed]

53. Cesana, M.; Cacchiarelli, D.; Legnini, I.; Santini, T.; Sthandier, O.; Chinappi, M.; Tramontano, A.; Bozzoni, I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell* **2011**, *147*, 358–369. [CrossRef] [PubMed]

54. Zhang, Z.K.; Li, J.; Guan, D.; Liang, C.; Zhuo, Z.; Liu, J.; Lu, A.; Zhang, G.; Zhang, B.T. A newly identified lncRNA MAR1 acts as a miR-487b sponge to promote skeletal muscle differentiation and regeneration. *J. Cachexia Sarcopenia Muscle* **2015**, *8*, 1911–1926. [CrossRef] [PubMed]

55. Mumford, P.W.; Romero, M.A.; Mao, X.; Mobley, C.B.; Kephart, W.C.; Haun, C.T.; Roberson, P.A.; Young, K.C.; Martin, J.S.; Yarrow, J.F.; et al. Cross talk between androgen and Wnt signaling potentially contributes to age-related skeletal muscle atrophy in rats. *J. Appl. Physiol. (1985)* **2018**, *125*, 486–494. [CrossRef] [PubMed]

56. Zhu, M.; Liu, J.; Xiao, J.; Yang, L.; Cai, M.; Shen, H.; Chen, X.; Ma, Y.; Hu, S.; Wang, Z.; et al. Lnc-mg is a long non-coding RNA that promotes myogenesis. *Nat. Commun.* **2017**, *8*, 14718. [CrossRef] [PubMed]

57. Du, J.; Zhang, P.; Zhao, X.; He, J.; Xu, Y.; Zou, Q.; Luo, J.; Shen, L.; Gu, H.; Tang, Q.; et al. MicroRNA-351-5p mediates skeletal myogenesis by directly targeting lactamase-beta and is regulated by lnc-mg. *FASEB J.* **2019**, *33*, 1911–1926. [CrossRef] [PubMed]

58. Gong, C.; Li, Z.; Ramanujan, K.; Clay, I.; Zhang, Y.; Lemire-Brachat, S.; Glass, D.J. A long non-coding RNA, LncMyoD, regulates skeletal muscle differentiation by blocking IMP2-mediated mRNA translation. *Dev. Cell* **2015**, *34*, 181–191. [CrossRef]

59. Song, C.; Wang, J.; Ma, Y.; Yang, Z.; Dong, D.; Li, H.; Yang, J.; Huang, Y.; Plath, M.; Ma, Y.; et al. Linc-smad7 promotes myoblast differentiation and muscle regeneration via sponging miR-125b. *Epigenetics* **2018**, *13*, 591–604. [CrossRef]

60. Liang, T.; Zhou, B.; Shi, L.; Wang, H.; Chu, Q.; Xu, F.; Li, Y.; Chen, R.; Shen, C.; Schinckel, A.P. LncRNA AK017368 promotes proliferation and suppresses differentiation of myoblasts in skeletal muscle development by attenuating the function of miR-30c. *FASEB J.* **2018**, *32*, 377–389. [CrossRef] [PubMed]

61. Guess, M.G.; Barthel, K.K.; Harrison, B.C.; Leinwand, L.A. miR-30 family microRNAs regulate myogenic differentiation and provide negative feedback on the microRNA pathway. *PLoS ONE* **2015**, *10*, e0118229. [CrossRef] [PubMed]

62. Lu, L.; Sun, K.; Chen, X.; Zhao, Y.; Wang, L.; Zhou, L.; Sun, H.; Wang, H. Genome-wide survey by ChIP-seq reveals YY1 regulation of lincRNAs in skeletal myogenesis. *EMBO J.* **2013**, *32*, 2575–2588. [CrossRef] [PubMed]

63. Wang, J.; Gong, C.; Maquat, L.E. Control of myogenesis by rodent SINE-containing lncRNAs. *FASEB J.* **2015**, *29*, 728–736. [CrossRef]

64. Ballarino, M.; Cazzella, V.; D’Andrea, D.; Grassi, L.; Bisceglie, L.; Cipriano, A.; Santini, T.; Pinnaro, C.; Tramontano, A.; et al. Novel long noncoding RNAs (lncRNAs) in myogenesis: A miR-31 overlapping lncRNA transcript controls myoblast differentiation. *FASEB J.* **2015**, *29*, 595–606. [CrossRef] [PubMed]

65. Dimartino, D.; Colantoni, A.; Ballarino, M.; Martone, J.; Mariani, D.; Danner, J.; Bruckmann, A.; Meister, G.; Morlando, M.; Bozzoni, I. The Long Non-coding RNA lnc-31 Interacts with Rock1 mRNA and Mediates Its YB-1-Dependent Translation. *Cell Rep.* **2018**, *23*, 733–740. [CrossRef] [PubMed]

66. Anderson, D.M.; Anderson, K.M.; Chang, C.L.; Makarewicz, C.A.; Nelson, B.R.; McAnally, J.R.; Kasaragod, P.; Shelton, J.M.; Liou, J.; Basset-Duby, R.; et al. A micropeptide encoded by a transcript annotated as long noncoding RNA regulates muscle performance. *Cell* **2015**, *160*, 595–606. [CrossRef] [PubMed]

67. Nelson, B.R.; Makarewicz, C.A.; Anderson, D.M.; Windsers, B.R.; Troupes, C.D.; Wu, F.; Reese, A.L.; McAnally, J.R.; Chen, X.; Kavalali, E.T.; et al. A peptide encoded by a transcript annotated as long noncoding RNA enhances SERCA activity in muscle. *Science* **2016**, *351*, 271–275. [CrossRef] [PubMed]

68. Quinn, M.E.; Goh, Q.; Kurosaka, M.; Gamage, D.G.; Petrany, M.J.; Prasad, V.; Millay, D.P. Myoenger induces fusion of non-fusogenic cells and is required for skeletal muscle development. *Nat. Commun.* **2017**, *8*, 15665. [CrossRef]
69. Bi, P.; Ramirez-Martinez, A.; Li, H.; Cannavino, J.; McAnally, J.R.; Shelton, J.M.; Sanchez-Ortiz, E.; Bassel-Duby, R.; Olson, E.N. Control of muscle formation by the fusogenic micropeptide myomixer. *Science* 2017, 356, 323–327. [CrossRef] [PubMed]

70. Zhang, Q.; Vashisht, A.A.; O'Rourke, J.; Corbel, S.Y.; Moran, R.; Romero, A.; Miraglia, L.; Zhang, J.; Durrant, E.; Schmedt, C.; et al. The microprotein Minion controls cell fusion and muscle formation. *Nat. Commun.* 2017, 8, 15664. [CrossRef]

71. Bi, P.; McAnally, J.R.; Shelton, J.M.; Sanchez-Ortiz, E.; Bassel-Duby, R.; Olson, E.N. Fusogenic micropeptide Myomixer is essential for satellite cell fusion and muscle regeneration. *Proc. Natl. Acad. Sci. USA* 2018, 115, 3864–3869. [CrossRef] [PubMed]

72. Matsumoto, A.; Pasut, A.; Matsumoto, M.; Yamashita, R.; Fung, J.; Monte Leone, E.; Saghatelian, A.; Nakayama, K.I.; Clohessy, J.G.; Pandolfi, P.P. mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. *Nature* 2017, 541, 228–232. [CrossRef] [PubMed]

73. Tajbakhsh, S. lncRNA-Encoded Polypeptide SPAR(s) with mTORC1 to Regulate Skeletal Muscle Regeneration. *Cell Stem Cell* 2017, 20, 428–430. [CrossRef] [PubMed]

74. Kallen, A.N.; Zhou, X.B.; Xu, J.; Qiao, C.; Ma, J.; Yan, L.; Lu, L.; Liu, C.; Yi, J.S.; Zhang, H.; et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. *Mol. Cell* 2013, 52, 101–112. [CrossRef] [PubMed]

75. Giovarelli, M.; Bucci, G.; Ramos, A.; Bordo, D.; Wilusz, C.J.; Chen, C.Y.; Puppo, M.; Briata, P.; Gherzi, R. H19 long noncoding RNA controls the mRNA decay promoting function of KSRP. *Proc. Natl. Acad. Sci. USA* 2014, 111, E5023–E5028. [CrossRef] [PubMed]

76. Dey, B.K.; Pfeifer, K.; Dutta, A. The H19 long noncoding RNA gives rise to microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle differentiation and regeneration. *Genes Dev.* 2014, 28, 491–501. [CrossRef] [PubMed]

77. Martinet, C.; Monnier, P.; Louault, Y.; Benard, M.; Gabory, A.; Dandolo, L. H19 controls reactivation of the imprinted gene network during muscle regeneration. *Development* 2016, 143, 962–971. [CrossRef] [PubMed]

78. Gabory, A.; Ripoche, M.A.; Le Digarcher, A.; Watrin, F.; Ziyyat, A.; Forne, T.; Jammes, H.; Ainscough, J.F.; Surani, M.A.; Journot, L.; et al. H19 acts as a trans regulator of the imprinted gene network controlling growth in mice. *Development* 2009, 136, 3413–3421. [CrossRef] [PubMed]

79. Park, K.S.; Mitra, A.; Rahat, B.; Kim, K.; Pfeifer, K. Loss of imprinting mutations define both distinct and overlapping roles for misexpression of IGF2 and of H19 lncRNA. *Nucleic Acids Res.* 2017, 45, 12766–12779. [CrossRef] [PubMed]

80. Wang, G.Q.; Wang, Y.; Xiong, Y.; Chen, X.C.; Ma, M.L.; Cai, R.; Gao, Y.; Sun, Y.M.; Yang, G.S.; Pang, W.J. Sirt1 AS lncRNA interacts with its mRNA to inhibit muscle formation by attenuating function of miR-34a. *Sci. Rep.* 2016, 6, 21865. [CrossRef]

81. Li, Z.; Cai, B.; Abdalla, B.A.; Zhu, X.; Zheng, M.; Han, P.; Nie, Q.; Zhang, X. LncIRS1 controls muscle atrophy via sponging miR-15 family to activate IGF1-PI3K/AKT pathway. *J. Cachexia Sarcopenia Muscle* 2019, 10, 391–410. [CrossRef] [PubMed]

82. Zhang, Z.K.; Li, J.; Guan, D.; Liang, C.; Zhuo, Z.; Liu, J.; Lu, A.; Zhang, G.; Zhang, B.T. Long Noncoding RNA IncMUMA Reverses Established Skeletal Muscle Atrophy following Mechanical Unloading. *Mol. Ther.* 2018, 26, 2669–2680. [CrossRef] [PubMed]

83. Cabianca, D.S.; Casa, V.; Bodega, B.; Xynos, A.; Ginelli, E.; Tanaka, Y.; Gabellini, D. A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. *Cell* 2012, 149, 819–831. [CrossRef] [PubMed]

84. Vizoso, M.; Esteller, M. The activatory long non-coding RNA DBE-T reveals the epigenetic etiology of facioscapulohumeral muscular dystrophy. *Cell Res.* 2012, 22, 1413–1415. [CrossRef] [PubMed]

85. Sun, L.; Si, M.; Liu, X.; Choi, J.M.; Wang, Y.; Thomas, S.S.; Peng, H.; Hu, Z. Long-noncoding RNA Atrolnc-1 promotes muscle wasting in mice with chronic kidney disease. *J. Cachexia Sarcopenia Muscle* 2018, 9, 962–974. [CrossRef] [PubMed]

86. Neppl, R.L.; Wu, C.L.; Walsh, K. IncRNA Chronos is an aging-induced inhibitor of muscle hypertrophy. *J. Cell Biol.* 2017, 216, 3497–3507. [CrossRef] [PubMed]

87. Sun, Q.; Hao, Q.; Prasanth, K.V. Nuclear Long Noncoding RNAs: Key Regulators of Gene Expression. *Trends Genet.* 2018, 34, 142–157. [CrossRef]
88. Kawaguchi, T.; Tanigawa, A.; Naganuma, T.; Ohkawa, Y.; Souquere, S.; Pierron, G.; Hirose, T. SWI/SNF chromatin-remodeling complexes function in noncoding RNA-dependent assembly of nuclear bodies. Proc. Natl. Acad. Sci. USA 2015, 112, 4304–4309. [CrossRef]
89. Zhu, Y.; Rowley, M.J.; Bohmdorfer, G.; Wierzbicki, A.T. A SWI/SNF chromatin-remodeling complex acts in noncoding RNA-mediated transcriptional silencing. Mol. Cell 2013, 49, 298–309. [CrossRef]
90. Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M.C.; Hung, T.; Argani, P.; Rinn, J.L.; et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464, 1071–1076. [CrossRef]
91. Ji, P.; Diederichs, S.; Wang, W.; Boing, S.; Metzger, R.; Schneider, P.M.; Tidow, B.; Buerger, H.; Bulk, E.; et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22, 8031–8041. [CrossRef] [PubMed]
92. Lin, R.; Maeda, S.; Liu, C.; Karin, M.; Edgington, T.S. A large noncoding RNA is a marker for murine dystrophy locus. Cell 2009, 137, 230. [CrossRef] [PubMed]
93. Zhao, Y.; Cao, F.; Yu, X.; Chen, C.; Meng, J.; Zhong, R.; Zhang, Y.; Zhu, D. Linc-RAM is required for FGF2 function in regulating myogenic cell differentiation. RNA Biol. 2015, 15, 404–412. [CrossRef] [PubMed]
94. Zhao, Y.; Cao, F.; Yu, X.; Chen, C.; Meng, J.; Zhong, R.; Zhang, Y.; Zhu, D. Linc-RAM is required for FGF2 function in regulating myogenic cell differentiation. RNA Biol. 2015, 15, 404–412. [CrossRef] [PubMed]
95. Orom, U.A.; Shiekhattar, R. Long noncoding RNAs usher in a new era in the biology of enhancers. Nat. Rev. Genet. 2014, 15, 1190–1193. [CrossRef] [PubMed]
96. Yoon, J.H.; Abdelmohsen, K.; Gorospe, M. Functional interactions among microRNAs and long noncoding RNAs. Semin. Cell Dev. Biol. 2014, 34, 9–14. [CrossRef] [PubMed]
97. He, L.; Chen, Y.; Hao, S.Q.; Qian, J.Q. Uncovering novel landscape of cardiovascular diseases and therapeutic targets for cardioprotection via long noncoding RNA-miRNA-mRNA axes. Epigenomics 2018, 10, 661–671. [CrossRef] [PubMed]
98. Militello, G.; Weirick, T.; John, D.; Doring, C.; Dimmeler, S.; Uchida, S. Screening and validation of lncRNAs and circRNAs as miRNA sponges. Epigenomics 2017, 9, 780–788. [CrossRef] [PubMed]
99. Thomson, D.W.; Dinger, M.E. Endogenous microRNA sponges: Evidence and controversy. Nat. Rev. Genet. 2016, 17, 272–283. [CrossRef] [PubMed]
100. Arase, M.; Horiguchi, K.; Ehata, S.; Morikawa, M.; Tsutsumi, S.; Aburatani, H.; Miyazono, K.; Koinuma, D. Transforming growth factor-beta-induced lncRNA-Smad7 inhibits apoptosis of mouse breast cancer JygMC(A) cells. Cancer Sci. 2014, 105, 974–982. [CrossRef] [PubMed]
101. Dykes, I.M.; Emanuelli, C. Transcriptional and Post-transcriptional Gene Regulation by Long Non-coding RNA. Genom. Proteom. Bioinform. 2017, 15, 177–186. [CrossRef] [PubMed]
102. Ruiz-Orera, J.; Messeguer, X.; Subirana, J.A.; Alba, M.M. Long non-coding RNAs as a source of new peptides. Elife 2014, 3, e03523. [CrossRef] [PubMed]
103. Andrews, S.J.; Rothnagel, J.A. Emerging evidence for functional peptides encoded by short open reading frames. Nat. Rev. Genet. 2014, 15, 193–204. [CrossRef] [PubMed]
104. Bazzini, A.A.; Johnstone, T.G.; Christiano, R.; Mackowiak, S.D.; Obermayer, B.; Fleming, E.S.; Vejnar, C.E.; Ji, P.; Diederichs, S.; Wang, W.; Boing, S.; Metzger, R.; Schneider, P.M.; Tidow, B.; Buerger, H.; Bulk, E.; et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22, 8031–8041. [CrossRef] [PubMed]
105. Rion, N.; Ruegg, M.A. LncRNA-encoded peptides: More than translational noise? Cell Res. 2017, 27, 604–605. [CrossRef] [PubMed]
106. Cai, B.; Li, Z.; Ma, M.; Wang, Z.; Han, P.; Abdalla, B.A.; Nie, Q.; Zhang, X. LncRNA-Six1 Encodes a Micropeptide to Activate Six1 in Cis and Is Involved in Cell Proliferation and Muscle Growth. Front. Physiol. 2017, 8, 230. [CrossRef] [PubMed]
107. da Rocha, S.T.; Edwards, C.A.; Ito, M.; Ogata, T.; Ferguson-Smith, A.C. Genomic imprinting at the mammalian Dlk1-Dio3 domain. Trends Genet. 2008, 24, 306–316. [CrossRef] [PubMed]
108. Davis, E.; Jensen, C.H.; Schroder, H.D.; Farnir, F.; Shay-Hadfield, T.; Kliem, A.; Cockett, N.; Georges, M.; Charlier, C. Ectopic expression of Dlk1 protein in skeletal muscle of padumal heterozygotes causes the callipigye phenotype. Curr. Biol. 2004, 14, 1858–1862. [CrossRef] [PubMed]
109. Hoffman, E.P.; Brown, R.H., Jr.; Kunkel, L.M. Dystrophin: The protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51, 919–928. [CrossRef]
110. Bovolenta, M.; Erriquez, D.; Valli, E.; Brioschi, S.; Scotton, C.; Neri, M.; Falzarano, M.S.; Gherardi, S.; Fabris, M.; Rimessi, P.; et al. The DMD locus harbours multiple long non-coding RNAs which orchestrate and control transcription of muscle dystrophin mRNA isoforms. PLoS ONE 2012, 7, e45328. [CrossRef]

111. Tonini, M.M.; Passos-Bueno, M.R.; Cerqueira, A.; Matioli, S.R.; Pavanello, R.; Zatz, M. Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD). Neuromuscul. Disord. 2004, 14, 33–38. [CrossRef]

112. Nie, M.; Deng, Z.L.; Liu, J.; Wang, D.Z. Noncoding RNAs, Emerging Regulators of Skeletal Muscle Development and Diseases. BioMed Res. Int. 2015, 2015, 676575. [CrossRef] [PubMed]

113. Hamann, P.D.; Roux, B.T.; Heward, J.A.; Love, S.; McHugh, N.J.; Jones, S.W.; Lindsay, M.A. Transcriptional profiling identifies differential expression of long non-coding RNAs in Jo-1 associated and inclusion body myositis. Sci. Rep. 2017, 7, 8024. [CrossRef] [PubMed]

114. Tabebordbar, M.; Wang, E.T.; Wagers, A.J. Skeletal muscle degenerative diseases and strategies for therapeutic muscle repair. Annu. Rev. Pathol. 2013, 8, 441–475. [CrossRef] [PubMed]

115. Thomson, D.M. The Role of AMPK in the Regulation of Skeletal Muscle Size, Hypertrophy, and Regeneration. Int. J. Mol. Sci. 2018, 19, 3125. [CrossRef] [PubMed]

116. Philippou, A.; Halapas, A.; Maridaki, M.; Koutsilieris, M. Type I insulin-like growth factor receptor signaling in skeletal muscle regeneration and hypertrophy. J. Musculoskelet Neuronal Interact 2007, 7, 208–218. [PubMed]

117. Zanou, N.; Gailly, P. Skeletal muscle hypertrophy and regeneration: Interplay between the myogenic regulatory factors (MRFs) and insulin-like growth factors (IGFs) pathways. Cell. Mol. Life Sci. 2013, 70, 4117–4130. [CrossRef] [PubMed]

118. Blaauw, B.; Schiaffino, S.; Reggiani, C. Mechanisms modulating skeletal muscle phenotype. Compr. Physiol. 2013, 3, 1645–1687. [CrossRef]

119. Blaauw, B.; Reggiani, C. The role of satellite cells in muscle hypertrophy. J. Muscle Res. Cell Motil. 2014, 35, 3–10. [CrossRef]

120. Lee, S.J.; Huynh, T.V.; Huynh, T.V.; Iwamori, N.; Lepper, C.; Matzuk, M.M.; Lee, S.J.; Huynh, T.V.; Iwamori, N.; Lepper, C.; Matzuk, M.M.; et al. BMP signaling controls muscle mass. Nat. Genet. 2013, 45, 1309–1318. [CrossRef] [PubMed]

121. Liu, M.; Li, B.; Peng, W.; Ma, Y.; Huang, Y.; Lan, X.; Lei, C.; Qi, X.; Liu, G.E.; Chen, H. LncRNA-MEG3 promotes bovine myoblast differentiation by sponging miR-135. J. Cell. Physiol. 2019, 234, 18361–18370. [CrossRef] [PubMed]

122. Sartori, R.; Schirwis, E.; Blaauw, B.; Bortolanza, S.; Zhao, J.; Enzo, E.; Stantzou, A.; Mouisel, E.; Toniolo, L.; Ferry, A.; et al. BMP signaling controls muscle mass. Nat. Genet. 2013, 45, 1309–1318. [CrossRef] [PubMed]

123. Liu, M.; Li, B.; Peng, W.; Ma, Y.; Huang, Y.; Lan, X.; Lei, C.; Qi, X.; Liu, G.E.; Chen, H. LncRNA-MEG3 promotes bovine myoblast differentiation by sponging miR-135. J. Cell. Physiol. 2019, 234, 18361–18370. [CrossRef] [PubMed]

124. Yu, X.; Wang, Z.; Sun, H.; Yang, Y.; Li, K.; Tang, Z. Long non-coding MEG3 is a marker for skeletal muscle development and meat production traits in pigs. Anim. Genet. 2018, 49, 571–578. [CrossRef] [PubMed]

125. Sun, X.; Li, M.; Sun, Y.; Cai, H.; Lan, X.; Huang, Y.; Bai, Y.; Qi, X.; Chen, H. The developmental transcriptome sequencing of bovine skeletal muscle reveals a long noncoding RNA, IncMD, promotes muscle differentiation by sponging miR-125b. Biochim. Biophys. Acta 2016, 1863, 2835–2845. [CrossRef] [PubMed]

126. Jin, C.F.; Li, Y.; Ding, X.B.; Li, X.; Zhang, L.L.; Liu, X.F.; Guo, H. Inc133b, a novel, long non-coding RNA, regulates bovine skeletal muscle satellite cell proliferation and differentiation by regulating miR-133b. Gene 2017, 670, 35–43. [CrossRef] [PubMed]

127. Li, H.; Yang, J.; Jiang, R.; Wei, X.; Song, C.; Huang, Y.; Lan, X.; Lei, C.; Ma, Y.; Hu, L.; et al. Long Non-coding RNA Profiling Reveals an Abundant MDNCR that Promotes Differentiation of Myoblasts by Sponging miR-133a. Mol. Ther. Nucleic Acids 2018, 12, 610–625. [CrossRef] [PubMed]

128. Xu, X.; Ji, S.; Li, W.; Yi, B.; Li, H.; Zhang, H.; Ma, W. LncRNA H19 promotes the differentiation of bovine skeletal muscle satellite cells by suppressing Sirt1/FoxO1. Cell. Mol. Biol. Lett. 2017, 22, 10. [CrossRef]

129. Yue, Y.; Jin, C.; Chen, M.; Zhang, L.; Liu, X.; Ma, W.; Guo, H. A lncRNA promotes myoblast proliferation by up-regulating GHI. In Vitro Cell. Dev. Biol. Anim. 2017, 53, 699–705. [CrossRef]

130. Chen, M.; Li, X.; Zhang, X.; Li, Y.; Zhang, J.; Liu, M.; Zhang, L.; Ding, X.; Liu, X.; Guo, H. A novel long non-coding RNA, IncKBTD10, involved in bovine skeletal muscle myogenesis. In Vitro Cell. Dev. Biol. Anim. 2019, 55, 25–35. [CrossRef]
111. Wei, C.; Wu, M.; Wang, C.; Liu, R.; Zhao, H.; Yang, L.; Liu, J.; Wang, Y.; Zhang, S.; Yuan, Z.; et al. Long Noncoding RNA Lnc-SEMT Modulates IGF2 Expression by Sponging miR-125b to Promote Sheep Muscle Development and Growth. *Cell. Physiol. Biochem.* 2018, 49, 447–462. [CrossRef] [PubMed]

112. Ma, M.; Cai, B.; Jiang, L.; Abdalla, B.A.; Li, Z.; Nie, Q.; Zhang, X. IncRNA-Six1 is a Target of miR-1611 that Functions as a ceRNA to Regulate Six1 Protein Expression and Fiber Type Switching in Chicken Myogenes. *Cells* 2018, 7, 243. [CrossRef] [PubMed]

113. Liang, G.; Yang, Y.; Li, H.; Yu, H.; Li, X.; Tang, Z.; Li, K. LncRNAset: A comprehensive Sus scrofa lncRNA database. *Anim. Genet.* 2018, 49, 632–635. [CrossRef] [PubMed]

114. Tang, Z.; Wu, Y.; Yang, Y.; Yang, Y.T.; Wang, Z.; Yuan, J.; Yang, Y.; Hua, C.; Fan, X.; Niu, G.; et al. Comprehensive analysis of long non-coding RNAs highlights their spatio-temporal expression patterns and evolutionary conservation in Sus scrofa. *Sci. Rep.* 2017, 7, 43166. [CrossRef] [PubMed]

115. Zou, C.; Li, J.; Luo, W.; Li, L.; Hu, A.; Fu, Y.; Hou, Y.; Li, C. Transcriptome analysis reveals long intergenic non-coding RNAs involved in skeletal muscle growth and development in pig. *Sci. Rep.* 2017, 7, 8704. [CrossRef] [PubMed]

116. Kern, C.; Wang, Y.; Chitwood, J.; Korf, L.; Delany, M.; Cheng, H.; Medrano, J.F.; van Eenennaam, A.L.; Ernst, C.; Ross, P.; et al. Genome-wide identification of tissue-specific long non-coding RNA in three farm animal species. *BMC Genom.* 2018, 19, 684. [CrossRef] [PubMed]

117. Sun, J.; Xie, M.; Huang, Z.; Li, H.; Chen, T.; Sun, R.; Wang, J.; Xi, Q.; Wu, T.; Zhang, Y. Integrated analysis of non-coding RNA and mRNA expression profiles of 2 pig breeds differing in muscle traits. *J. Anim. Sci.* 2017, 95, 1092–1103. [CrossRef] [PubMed]

118. Zou, C.; Li, S.; Deng, L.; Guan, Y.; Chen, D.; Yuan, X.; Xia, T.; He, X.; Shan, Y.; Li, C. Transcriptome Analysis Reveals Long Intergenic Noncoding RNAs Contributed to Growth and Meat Quality Differences between Yorkshire and Wannanhua Pig. *Genes (Basel)* 2017, 8, 203. [CrossRef] [PubMed]

119. Ren, H.; Li, Y.; Tang, Z.; Yang, S.; Mu, Y.; Cui, W.; Ao, H.; Du, L.; Wang, L.; Li, K. Genomic structure, chromosomal localization and expression profile of a porcine long non-coding RNA isolated from long SAGE libraries. *Anim. Genet.* 2009, 40, 499–508. [CrossRef] [PubMed]

120. Zhao, W.; Mu, Y.; Ma, L.; Wang, C.; Tang, Z.; Yang, S.; Zhou, R.; Hu, X.; Li, M.H.; Li, K. Systematic identification and characterization of long intergenic non-coding RNAs in fetal porcine skeletal muscle development. *Sci. Rep.* 2015, 5, 8957. [CrossRef]

121. Billerey, C.; Boussaha, M.; Esquerre, D.; Rebouris, E.; Djari, A.; Meersseman, C.; Klopp, C.; Gautheret, D.; Rocha, D. Identification of large intergenic non-coding RNAs in bovine muscle using next-generation transcriptomic sequencing. *BMC Genom.* 2014, 15, 499. [CrossRef] [PubMed]

122. Koufariotis, L.T.; Chen, Y.P.; Chamberlain, A.; Vander Jagt, C.; Hayes, B.J. A catalogue of novel bovine long noncoding RNA across 18 tissues. *PLoS ONE* 2015, 10, e0141225. [CrossRef] [PubMed]

123. Liu, X.F.; Ding, X.B.; Li, X.; Jin, C.F.; Yue, Y.W.; Li, G.P.; Guo, H. An atlas and analysis of bovine skeletal muscle long noncoding RNAs. *Anim. Genet.* 2017, 48, 278–286. [CrossRef] [PubMed]

124. Zhan, S.; Dong, Y.; Zhao, W.; Guo, J.; Zhong, T.; Wang, L.; Li, L.; Zhang, H. Genome-wide identification and characterization of long non-coding RNAs in developmental skeletal muscle of fetal goat. *BMC Genom.* 2016, 17, 666. [CrossRef] [PubMed]

125. Ren, C.; Deng, M.; Fan, Y.; Yang, H.; Zhang, G.; Feng, X.; Li, F.; Wang, D.; Wang, F.; Zhang, Y. Genome-Wide Analysis Reveals Extensive Changes in LncRNAs during Skeletal Muscle Development in Hu Sheep. *Genes (Basel)* 2017, 8, 191. [CrossRef] [PubMed]

126. Li, C.Y.; Li, X.; Liu, Z.; Ni, W.; Zhang, X.; Hazi, W.; Ma, Q.; Zhang, Y.; Cao, Y.; Qi, J.; et al. Identification and characterization of long non-protein coding RNA in prenatal and postnatal skeletal muscle of sheep. *Genomics* 2019, 111, 133–141. [CrossRef] [PubMed]

127. Li, T.; Wang, S.; Wu, R.; Zhou, X.; Zhu, D.; Zhang, Y. Identification of long non-protein coding RNAs in chicken skeletal muscle using next generation sequencing. *Genomics* 2012, 99, 292–298. [CrossRef] [PubMed]

128. Li, Z.; Ouyang, H.; Zheng, M.; Cai, B.; Han, P.; Abdalla, B.A.; Nie, Q.; Zhang, X. Integrated Analysis of Long Non-coding RNAs (LncRNAs) and mRNA Expression Profiles Reveals the Potential Role of LncRNAs in Skeletal Muscle Development of the Chicken. *Front. Physiol.* 2016, 7, 687. [CrossRef]

129. Li, T.; Zhang, G.; Wu, P.; Duan, L.; Li, G.; Liu, Q.; Wang, J. Dissection of Myogenic Differentiation Signatures in Chickens by RNA-Seq Analysis. *Genes (Basel)* 2018, 9, 34. [CrossRef]
150. Li, D.; Li, F.; Jiang, K.; Zhang, M.; Han, R.; Jiang, R.; Li, Z.; Tian, Y.; Yan, F.; Kang, X.; et al. Integrative analysis of long noncoding RNA and mRNA reveals candidate lncRNAs responsible for meat quality at different physiological stages in Gushi chicken. PLoS ONE 2019, 14, e0215006. [CrossRef] [PubMed]

151. Ren, T.; Li, Z.; Zhou, Y.; Liu, X.; Han, R.; Wang, Y.; Yan, F.; Sun, G.; Li, H.; Kang, X. Sequencing and characterization of lncRNAs in the breast muscle of Gushi and Arbor Acres chickens. Genome 2018, 61, 337–347. [CrossRef] [PubMed]

152. Evers, B.; Jastrzebski, K.; Heijmans, J.P.; Grernrum, W.; Beijersbergen, R.L.; Bernards, R. CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes. Nat. Biotechnol. 2016, 34, 631–633. [CrossRef] [PubMed]

153. Gilbert, L.A.; Horlbeck, M.A.; Adamson, B.; Villalta, J.E.; Chen, Y.; Whitehead, E.H.; Guimaraes, C.; Panning, B.; Ploegh, H.L.; Bassik, M.C.; et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 2014, 159, 647–661. [CrossRef] [PubMed]

154. Goyal, A.; Myacheva, K.; Gross, M.; Klingenberg, M.; Duran Arque, B.; Diederichs, S. Challenges of CRISPR/Cas9 applications for long non-coding RNA genes. Nucleic Acids Res. 2017, 45, e12. [CrossRef] [PubMed]

155. Cao, H.; Wahlestedt, C.; Kapranov, P. Strategies to Annotate and Characterize Long Noncoding RNAs: Advantages and Pitfalls. Trends Genet. 2018, 34, 704–721. [CrossRef] [PubMed]

156. Chen, X.; Yan, C.C.; Zhang, X.; You, Z.H. Long non-coding RNAs and complex diseases: From experimental results to computational models. Brief. Bioinform. 2017, 18, 558–576. [CrossRef] [PubMed]

157. Chen, X.; Sun, Y.Z.; Guan, N.N.; Qu, J.; Huang, Z.A.; Zhu, Z.X.; Li, J.Q. Computational models for lncRNA function prediction and functional similarity calculation. Brief. Funct. Genom. 2019, 18, 58–82. [CrossRef] [PubMed]

158. Zhang, Z.; Zhang, J.; Fan, C.; Tang, Y.; Deng, L. KATZLGO: Large-Scale Prediction of LncRNA Functions by Using the KATZ Measure Based on Multiple Networks. IEEE/ACM Trans. Comput. Biol. Bioinform. 2019, 16, 407–416. [CrossRef]

159. Yotsukura, S.; duVerle, D.; Hancock, T.; Natsume-Kitatani, Y.; Mamitsuka, H. Computational recognition for long non-coding RNA (lncRNA): Software and databases. Brief. Bioinform. 2017, 18, 9–27. [CrossRef] [PubMed]

160. Mas-Ponte, D.; Carlevaro-Fita, J.; Palumbo, E.; Hermos Puido, T.; Guigo, R.; Johnson, R. LncATLAS database for subcellular localization of long noncoding RNAs. RNA 2017, 23, 1080–1087. [CrossRef]

161. Chang, T.H.; Huang, H.Y.; Hsu, J.B.; Weng, S.L.; Horng, J.T.; Huang, H.D. An enhanced computational platform for investigating the roles of regulatory RNA and for identifying functional RNA motifs. BMC Bioinform. 2013, 14 (Suppl. 2). [CrossRef]

162. Li, J.H.; Liu, S.; Zhou, H.; Qu, L.H.; Yang, J.H. starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014, 42, D92–D97. [CrossRef] [PubMed]

163. Muppirala, U.K.; Honavar, V.G.; Dobbs, D. Predicting RNA-protein interactions using only sequence information. BMC Bioinform. 2011, 12, 489. [CrossRef] [PubMed]

164. Bar, C.; Chatterjee, S.; Thum, T. Long Noncoding RNAs in Cardiovascular Pathology, Diagnosis, and Therapy. Circulation 2016, 134, 1484–1499. [CrossRef] [PubMed]

165. Beermann, J.; Piccoli, M.T.; Viereck, J.; Thum, T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiol. Rev. 2016, 96, 1297–1325. [CrossRef] [PubMed]

166. McMullen, J.R.; Drew, B.G. Long non-coding RNAs (lncRNAs) in skeletal and cardiac muscle: Potential therapeutic and diagnostic targets? Clin. Sci. (Lond.) 2016, 130, 2245–2256. [CrossRef]

167. Boon, R.A.; Jae, N.; Holtd, L.; Dommmer, S. Long Noncoding RNAs: From Clinical Genetics to Therapeutic Targets? J. Am. Coll. Cardiol. 2016, 67, 1214–1226. [CrossRef]

168. Chandra Gupta, S.; Nandan Tripathi, Y. Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int. J. Cancer 2017, 140, 1955–1967. [CrossRef]